Analysts See $-0.58 EPS for Kala Pharmaceuticals, Inc. (KALA)

October 13, 2018 - By Ruchi Gupta

Analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report $-0.58 EPS on November, 6.They anticipate $0.02 EPS change or 3.57 % from last quarter’s $-0.56 EPS. After having $-0.60 EPS previously, Kala Pharmaceuticals, Inc.’s analysts see -3.33 % EPS growth. The stock increased 6.20% or $0.5 during the last trading session, reaching $8.56. About 874,686 shares traded or 157.35% up from the average. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has declined 58.41% since October 14, 2017 and is downtrending. It has underperformed by 74.03% the S&P500.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $274.83 million. The company??s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

More notable recent Kala Pharmaceuticals, Inc. (NASDAQ:KALA) news were published by: Nasdaq.com which released: “Here’s Why Kala Pharmaceuticals Fell as Much as 17.7% Today” on October 03, 2018, also Benzinga.com with their article: “32 Stocks Moving In Monday’s Pre-Market Session” published on October 08, 2018, Businesswire.com published: “Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares” on October 11, 2018. More interesting news about Kala Pharmaceuticals, Inc. (NASDAQ:KALA) were released by: Streetinsider.com and their article: “Pre-Open Movers 10/03: (ELGX) (JCP) (TPX) Higher; (DTEA) (CENX) (KALA) Lower (more…)” published on October 03, 2018 as well as Seekingalpha.com‘s news article titled: “Kala Pharma +8.7% as shareholder discloses $20M purchase” with publication date: October 05, 2018.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>